MECHANISM OF ACTION
KPV is one of the smallest peptides studied for inflammation, just three amino acids (building blocks) linked together. It comes from a larger hormone your body already makes. Despite its tiny size, it powerfully switches off the signals that cause inflammation inside cells. What makes it interesting is that it works especially well in the gut: when taken orally, it gets absorbed directly through the intestinal lining and acts locally where it lands. KLOW is a related compound often paired with KPV to cover a broader range of inflammation pathways.
RESEARCH APPLICATIONS
- Inflammatory bowel disease and gut mucosal repair models
- Skin inflammation and wound recovery (topical and systemic)
- Systemic anti-inflammatory research (NF-κB pathway)
- Gut-brain axis inflammation modelling
- Post-injury tissue recovery stacks (with BPC-157)
RESEARCH HIGHLIGHTS
IBD Mucosal Protection
2010KPV incorporated into hydrogel nanoparticles delivered orally demonstrated significant reduction in colitis markers (MPO, TNF-α, IL-6) vs. controls in preclinical colitis models.
Ref: Laroui et al., Gastroenterology
NF-κB Anti-Inflammatory Mechanism
2008KPV inhibits NF-κB nuclear translocation independently of MC1R binding, suggesting a direct intracellular anti-inflammatory mechanism distinct from α-MSH.
Ref: Brzoska et al., Peptides
RESEARCH PROTOCOL NOTES
Chemical Identity
Sequence
Lys-Pro-Val
Storage & Stability
Lyophilised: -20°C. Reconstituted: 2–8°C, use within 14 days. Small tripeptide - less stable in solution than larger peptides.
Regulatory Status
Research compound. No regulatory approval. Not WADA listed. SAHPRA: unscheduled research compound.